FAQs
What is the average life expectancy for small cell lung cancer with treatment?
For extensive‑stage disease, median survival with modern chemo‑immunotherapy is about 7–11 months; limited‑stage patients can see 12–16 months.
How does adding immunotherapy change survival?
Adding a PD‑L1 inhibitor (atezolizumab or durvalumab) to platinum‑based chemo adds roughly 2–3 months to median overall survival and raises the chance of long‑term remission.
Can patients with small cell lung cancer live beyond five years?
Yes, a small minority (around 5 % of limited‑stage and 15–20 % of extensive‑stage patients) can survive five years or more, especially when they receive aggressive multimodal therapy and have good performance status.
What factors most influence survival outcomes?
Key factors include stage at diagnosis, age, performance status (ECOG 0‑1), smoking history, comorbidities, and tumor biology. Access to clinical trials also improves odds.
What are the main treatment options for extensive‑stage disease?
The standard first‑line regimen is platinum‑based chemotherapy (cisplatin or carboplatin plus etoposide) combined with a PD‑L1 inhibitor. Radiation is used for symptom control and prophylactic cranial irradiation may be offered after response.
